Difference between revisions of "QIBA Profile Conformance"
Jump to navigation
Jump to search
| (69 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
{{TOCright}} | {{TOCright}} | ||
| + | |||
| + | |||
| + | [[Image:QIBA_WIKI_BLURB.jpg|600px]] | ||
| + | |||
== <font color=green>'''Self-attestation (Registered) or QIBA Tested (Certified) Opportunities'''</font> == | == <font color=green>'''Self-attestation (Registered) or QIBA Tested (Certified) Opportunities'''</font> == | ||
| Line 10: | Line 14: | ||
::[[Image:Profile Conformance Image3.png|500px]] | ::[[Image:Profile Conformance Image3.png|500px]] | ||
| − | + | == <font color=purple>'''Certification Service for Conformance'''</font> == | |
| − | |||
| − | == <font color=purple>''' | ||
===CT Small Lung Nodule Volumetry for Screening=== | ===CT Small Lung Nodule Volumetry for Screening=== | ||
*[[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean-2.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]] | *[[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean-2.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]] | ||
| + | |||
*https://www.rsna.org/en/research/quantitative-imaging-biomarkers-alliance/qiba-conformance-certification-services | *https://www.rsna.org/en/research/quantitative-imaging-biomarkers-alliance/qiba-conformance-certification-services | ||
| + | ===DWI-MRI (ADC Change) Profile v2022=== | ||
| + | |||
| + | *[[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC) 2022-12-15]] | ||
| + | *QIBA Conformance Certification for the DWI Profile – Please visit [https://qmri.com/ '''<font color=blue>Caliber MRI</font>'''] | ||
== <font color=green>'''Self Attestation of Conformance'''</font> == | == <font color=green>'''Self Attestation of Conformance'''</font> == | ||
The following QIBA Profiles have reached the Consensus Stage or the Technically Confirmed Stage, and are thus appropriate for self-attestation conformance testing. | The following QIBA Profiles have reached the Consensus Stage or the Technically Confirmed Stage, and are thus appropriate for self-attestation conformance testing. | ||
| + | |||
| + | See '''[[Profile Conformance]]''' | ||
===CT: Lung Tumor Volume (Advanced Disease)=== | ===CT: Lung Tumor Volume (Advanced Disease)=== | ||
| − | '''Profile''' | + | :'''Profile''' |
| − | * [[Media:QIBA_CTVol_TumorVolumeChangeProfile_TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]] | + | :* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]] |
| − | '''Checklist''' | + | :'''Checklist''' |
| − | * [[Media: QIBA_CTVol_TumorVolumeChangeProfile-Conformance Testing_Checklist_20191111.pdf | | + | :* [[Media: QIBA_CTVol_TumorVolumeChangeProfile-Conformance Testing_Checklist_20191111.pdf | Conformance Checklist]] (contains Appendix C extracted from the Profile document - pg 42) |
| − | + | :* [[Media:QIBA_CTVol_TumorVolumeChangeProfile-Conformance Testing_Supplement_2019051111.pdf | Assessment Procedures]] (contains Section 4 extracted from the Profile document - pg 30) | |
| − | :*[[Media:QIBA_CTVol_TumorVolumeChangeProfile-Conformance Testing_Supplement_2019051111.pdf | | + | :'''Report Template''' |
| − | '''Report Template''' | + | :*[[Media:QIBA_Conformance_Statement-Self-Attestation_CTvolAD_20191111-confirmed.pdf | Conformance Statement - Self-Attestation]] |
| − | :*[[Media:QIBA_Conformance_Statement-Self-Attestation_CTvolAD_20191111-confirmed.pdf | | ||
===FDG-PET: Solid Tumor SUV=== | ===FDG-PET: Solid Tumor SUV=== | ||
| − | '''Profile''' | + | :'''Profile''' |
| − | * [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]] | + | :* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]] |
| − | '''Checklist''' | + | |
| − | * [[Media: | + | :'''Checklist for sites''' |
| − | ''' | + | :* [[Media:2021-03-31.pdf | QIBA FDG-PET/CT Conformance Checklist 2021-03-31]] |
| − | * [ | + | |
| + | |||
| + | :'''Checklist for clinical trial''' | ||
| + | |||
| + | |||
| + | :'''Reporting''' | ||
| + | :*Please fill out your respective checklist and [mailto:qiba@rsna.org Email QIBA] for conformance assessment. | ||
===DWI MR: ADC of Lesions in Four Organs=== | ===DWI MR: ADC of Lesions in Four Organs=== | ||
| − | '''Profile''' | + | :'''Profile''' |
| − | *[[Media: | + | |
| − | '''Checklist''' | + | :*[[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC) 2022-12-15]] |
| − | *[[Media: | + | |
| − | **[[Media: | + | :'''Checklist for sites''' |
| − | + | ||
| − | ''' | + | :*[[Media:QIBA_DWIProfile_Stage3_15Dec2022_CheckLists.pdf | QIBA DWI-MRI Conformance Checklist, 2022-12-15]] |
| − | *[[Media: | + | :**[[Media:QIBA_DWI_Profile__Conformance_Testing_Supplement_1_v2023nov2_nonQIDW.pdf | QIBA DWI Conformance Testing Supplement #1, 2023-11-02]] |
| + | |||
| + | :'''Checklist for software providers''' | ||
| + | |||
| + | :*[[Media:QIBA_DWI_Profile_SW_Provider_Conformance-Testing_Checklist_20210601.pdf | QIBA DWI-MRI Conformance Checklist, 2021-06-01]] | ||
| + | :**[[Media:QIBA_DWI_Profile__Conformance_Testing_Supplement_1_v2023nov2_nonQIDW.pdf | QIBA DWI Conformance Testing Supplement #1, 2023-11-02]] | ||
| + | |||
| + | :'''Checklist for clinical trial''' | ||
| + | |||
| + | :*[[Media:QIBA_DWIProfile_Stage3_15Dec2022_CheckLists.pdf | QIBA DWI-MRI Conformance Checklist, 2022-12-15]] | ||
| + | :**[[Media:QIBA_DWI_Profile__Conformance_Testing_Supplement_1_v2023nov2_nonQIDW.pdf | QIBA DWI Conformance Testing Supplement #1, 2023-11-02]] | ||
| + | |||
| + | :'''Reporting''' | ||
| + | :*Please fill out your respective checklist and [mailto:qiba@rsna.org Email QIBA] for conformance assessment. | ||
==<font color=blue>'''[[List of Registered Conformant Users (Self-attestation)]]'''</font>== | ==<font color=blue>'''[[List of Registered Conformant Users (Self-attestation)]]'''</font>== | ||
==<font color=blue>'''[[List of Certified Conformant Users (QIBA Tested)]]'''</font>== | ==<font color=blue>'''[[List of Certified Conformant Users (QIBA Tested)]]'''</font>== | ||
Latest revision as of 21:05, 4 January 2024
Self-attestation (Registered) or QIBA Tested (Certified) Opportunities
{This content will eventually be available on the RSNA.org website.}
QIBA Profiles that are at least at the Consensus Stage are available to interested parties (clinical sites, CROs, equipment and/or software vendors) to demonstrate that all relevant actors of an institution or product conform to the respective QIBA Profile.
As shown in the following diagram, QIBA Profile conformance may be demonstrated via Self Attestation, or (when available) via a Certification service:
Certification Service for Conformance
CT Small Lung Nodule Volumetry for Screening
DWI-MRI (ADC Change) Profile v2022
- MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC) 2022-12-15
- QIBA Conformance Certification for the DWI Profile – Please visit Caliber MRI
Self Attestation of Conformance
The following QIBA Profiles have reached the Consensus Stage or the Technically Confirmed Stage, and are thus appropriate for self-attestation conformance testing.
CT: Lung Tumor Volume (Advanced Disease)
- Profile
- Checklist
- Conformance Checklist (contains Appendix C extracted from the Profile document - pg 42)
- Assessment Procedures (contains Section 4 extracted from the Profile document - pg 30)
- Report Template
FDG-PET: Solid Tumor SUV
- Checklist for sites
- Checklist for clinical trial
- Reporting
- Please fill out your respective checklist and Email QIBA for conformance assessment.
DWI MR: ADC of Lesions in Four Organs
- Profile
- Checklist for sites
- Checklist for software providers
- Checklist for clinical trial
- Reporting
- Please fill out your respective checklist and Email QIBA for conformance assessment.